{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 3739, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a horizontal timeline format to map product milestones against calendar years.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/17", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-17", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "roadmap", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/18", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-18", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/19", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 19, "beatId": "2d505f6d-74d8-451e-ae4d-1226e5a58880", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The leadership team and advisors are presented on pages 19-20", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid layout to present 10 advisors, each with a headshot, name, role, and company logo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/20", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 19, "beatId": "2d505f6d-74d8-451e-ae4d-1226e5a58880", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "The leadership team and advisors are presented on pages 19-20", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a DNA helix as a creative timeline background, reflecting the company's focus on molecular diagnostics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/21", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-21", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "appendix_data", "function": "analyze_data", "notes": "Includes income statement metrics, balance sheet data, and equity structure.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/22", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-22", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "executive_summary", "function": "summarize", "notes": "The slide uses a grid-like layout to present six key value propositions surrounding a central product image.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/23", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 23, "beatId": "0b99a22a-e5c5-4f80-87c4-3c78596c4dd6", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Investment Ask", "beatSlug": "sequoia-pitch-the-ask", "evidence": "The investment highlights and thank you slide are presented on pages 23-24", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-862c-74eb-a1c6-035540787a6a", "docSlug": "0c16cbe7f9f11d0d4dde4442bc0ea51b", "documentTitle": "Mainz Biomed NV | Investor Presentation Deck | 24 slides", "authorId": "mainz-biomed-nv", "authorName": "Mainz Biomed", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "closing_ask", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-862c-74eb-a1c6-035540787a6a/24", "deckHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a", "deckAnchorHref": "/decks/019de076-862c-74eb-a1c6-035540787a6a#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 23, "beatId": "0b99a22a-e5c5-4f80-87c4-3c78596c4dd6", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Investment Ask", "beatSlug": "sequoia-pitch-the-ask", "evidence": "The investment highlights and thank you slide are presented on pages 23-24", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Includes company logo, name, ticker symbol, and date.", "imagePath": "https://imgproxy.kitesheet.com/o8ib4hPsRE4T6-yOiXVBDvrBEvAPwJD6wL1RXLST_lU/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTIzNzg0NDYyYTEzMTA5M2NiMTE4MzEzZjcwNTk3YS9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/1", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/sveHEyIiT2HSUVminANZ2UPJQjXyjjdvD9ayWUjIYsY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTIzNzg0NDYyYTEzMTA5M2NiMTE4MzEzZjcwNTk3YS9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/Cel3Ge-icw_Yg1PJRrig4HbVRDs7glnkR_ADK44xuZY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTIzNzg0NDYyYTEzMTA5M2NiMTE4MzEzZjcwNTk3YS9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/xWMJdFqCC1cqqoBYGZTGVBl9mElMc5foYNGLtVJEL3U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zYTIzNzg0NDYyYTEzMTA5M2NiMTE4MzEzZjcwNTk3YS9wMDAxLnBuZw" }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/2", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "team_bio", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/3", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-3", "loopMatches": [], "arcBeatMatches": [ { "to": 3, "from": 3, "beatId": "12c1a744-a564-443d-af1b-dbe8a50ca0cb", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Team", "beatSlug": "sequoia-pitch-team", "evidence": "Slide 3 highlights the strong leadership team", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/4", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-4", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 4, "beatId": "dbe82cfe-75f2-4785-9d67-d732f6043b6b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slides 4-5 discuss the target market and pipeline", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a standard pharmaceutical pipeline table format.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/5", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 4, "beatId": "dbe82cfe-75f2-4785-9d67-d732f6043b6b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Problem", "beatSlug": "sequoia-pitch-problem", "evidence": "Slides 4-5 discuss the target market and pipeline", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "roadmap", "function": "plan_implementation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/6", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/7", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 11, "from": 7, "beatId": "5ab81c27-84ad-4636-b15d-fb51c59b7f9b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-11 detail the solution, including DA-1241 and its effects", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The table highlights clinical status, mechanism of action, efficacy, safety, and strategic differentiation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/8", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-8", "loopMatches": [ { "to": 11, "from": 8, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "12d85908-f74a-4938-912e-444c9b3e39a3", "evidence": "Slides 8-11 discuss DA-1241's competitive differentiation and effects", "position": 0, "objective": "What sets DA-1241 apart from existing treatments?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.6, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 11, "from": 7, "beatId": "5ab81c27-84ad-4636-b15d-fb51c59b7f9b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-11 detail the solution, including DA-1241 and its effects", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological process flow to explain the mechanism of action.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/9", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-9", "loopMatches": [ { "to": 11, "from": 8, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "12d85908-f74a-4938-912e-444c9b3e39a3", "evidence": "Slides 8-11 discuss DA-1241's competitive differentiation and effects", "position": 0, "objective": "What sets DA-1241 apart from existing treatments?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.6, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 11, "from": 7, "beatId": "5ab81c27-84ad-4636-b15d-fb51c59b7f9b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-11 detail the solution, including DA-1241 and its effects", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "solution", "function": "present_solution", "notes": "Includes two heatmaps showing gene expression changes and a biological pathway diagram for GLP1 receptor activation.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/10", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-10", "loopMatches": [ { "to": 11, "from": 8, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "12d85908-f74a-4938-912e-444c9b3e39a3", "evidence": "Slides 8-11 discuss DA-1241's competitive differentiation and effects", "position": 0, "objective": "What sets DA-1241 apart from existing treatments?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.6, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 11, "from": 7, "beatId": "5ab81c27-84ad-4636-b15d-fb51c59b7f9b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-11 detail the solution, including DA-1241 and its effects", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "product_demo", "function": "analyze_data", "notes": "Includes study references and definitions for GPR119, MASH, GLP-1, and drug dosages.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/11", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-11", "loopMatches": [ { "to": 11, "from": 8, "name": "Pattern Hunter", "slug": "02-pattern-hunter", "bestFor": "Time-pressed audiences, building consensus, when data is strong", "matchId": "12d85908-f74a-4938-912e-444c9b3e39a3", "evidence": "Slides 8-11 discuss DA-1241's competitive differentiation and effects", "position": 0, "objective": "What sets DA-1241 apart from existing treatments?", "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion", "confidence": 0.6, "description": "Group multiple pieces of evidence that together point to a pattern or conclusion" } ], "arcBeatMatches": [ { "to": 11, "from": 7, "beatId": "5ab81c27-84ad-4636-b15d-fb51c59b7f9b", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "Slides 7-11 detail the solution, including DA-1241 and its effects", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide presents 11 distinct bar charts summarizing a study on drug efficacy in a mouse model of MASH (Metabolic dysfunction-associated steatohepatitis).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/12", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "traction", "function": "show_traction", "notes": "Notes at bottom define FPFV and LPO.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/13", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "unfair_advantage", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of the drug target.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/14", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "cover", "function": "front_matter", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/15", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The table highlights DA-1726's dual agonist mechanism and potential for better tolerability compared to market leaders.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/16", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-16", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/17", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide uses three charts: a bar chart for food intake and two line charts for body weight loss (BWL) in different mouse models.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/18", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-18", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "competitive_analysis", "function": "compare_peers", "notes": "The slide highlights that DA-1726 achieves weight loss through mechanisms other than just food reduction, as evidenced by higher food intake compared to Tirzepatide.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/19", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-19", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "appendix_methodology", "function": "analyze_data", "notes": "Includes study design, population, and location details.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/20", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 20, "from": 13, "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/21", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 21, "beatId": "cc3c5e8b-cf56-4d3b-9b42-acefa20a440d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slides 21-22 present financials and capitalization information", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "appendix_data", "function": "analyze_data", "notes": "WAEP stands for Weighted Average Exercise Price.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/22", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 22, "from": 21, "beatId": "cc3c5e8b-cf56-4d3b-9b42-acefa20a440d", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Financials", "beatSlug": "sequoia-pitch-financials", "evidence": "Slides 21-22 present financials and capitalization information", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "thesis_headline", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/23", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-23", "loopMatches": [ { "to": 24, "from": 23, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "2d1fd31a-1e17-421e-99fe-ab78f0c7a3f8", "evidence": "Slides 23-24 present the investment thesis and compelling opportunity", "position": 1, "objective": "Why is now the right time to invest in NeuroBo Pharmaceuticals?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/24", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-24", "loopMatches": [ { "to": 24, "from": 23, "name": "Why Now", "slug": "15-why-now", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "matchId": "2d1fd31a-1e17-421e-99fe-ab78f0c7a3f8", "evidence": "Slides 23-24 present the investment thesis and compelling opportunity", "position": 1, "objective": "Why is now the right time to invest in NeuroBo Pharmaceuticals?", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "confidence": 0.6, "description": "Create temporal urgency by proving that the window of opportunity is opening or closing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-86c0-778c-b811-8ed1a345f3e4", "docSlug": "3a23784462a131093cb118313f70597a", "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides", "authorId": "neurobo-pharmaceuticals", "authorName": "NeuroBo Pharmaceuticals", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "closing_ask", "function": "state_next_steps", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/25", "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4", "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-25", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 1, "slideType": "cover", "function": "front_matter", "notes": "Features a scientific illustration of a synapse.", "imagePath": "https://imgproxy.kitesheet.com/iryd0s10LwWIlQme5gode11fVddR6F-YhSmOX4qJzWw/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81NjAxNzZiNDEwYTcyYTZiMmU2N2FmNWRkMmEyMDc1OC9wMDAxLmpwZw", "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/1", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/KoTUF1qeTqrE27F31yd72C61X2BDong-C94ICYAWYfA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81NjAxNzZiNDEwYTcyYTZiMmU2N2FmNWRkMmEyMDc1OC9wMDAxLnBuZw", "thumbSrc": "https://imgproxy.kitesheet.com/941_YkXfu9e9VGY7PQUtJ7VdO9qWiyowTPdyBBCSt1U/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81NjAxNzZiNDEwYTcyYTZiMmU2N2FmNWRkMmEyMDc1OC9wMDAxLmpwZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/JJhBIB3FFVy4qNZhcr4kc1toyvGDNWmgrCOAUTNlEBg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy81NjAxNzZiNDEwYTcyYTZiMmU2N2FmNWRkMmEyMDc1OC9wMDAxLnBuZw" }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/2", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 3, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/3", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 4, "slideType": "roadmap", "function": "plan_implementation", "notes": "The slide uses a standard pharmaceutical pipeline visualization format.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/4", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 5, "slideType": "problem_statement", "function": "frame_problem", "notes": "Uses a personal narrative (Shay) to humanize the disease progression alongside clinical data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/5", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-5", "loopMatches": [], "arcBeatMatches": [ { "to": 5, "from": 5, "beatId": "0c6dc7ee-9e73-4f02-a0ba-70360d2eb84a", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "The document identifies ALS as a significant problem, highlighting its debilitating nature and limited treatment options.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" }, { "to": 6, "from": 5, "beatId": "d139c8b0-bfb8-4e22-92c8-f4d01b6477cc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document agitates the problem by highlighting the limitations and side effects of current ALS treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/6", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-6", "loopMatches": [], "arcBeatMatches": [ { "to": 6, "from": 5, "beatId": "d139c8b0-bfb8-4e22-92c8-f4d01b6477cc", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "The document agitates the problem by highlighting the limitations and side effects of current ALS treatments.", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" }, { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 7, "slideType": "solution", "function": "present_solution", "notes": "The slide uses a combination of a biological process diagram and a pharmacokinetic line chart to demonstrate drug synergy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/7", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-7", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 8, "slideType": "traction", "function": "show_traction", "notes": "The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/8", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-8", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 9, "slideType": "solution", "function": "present_solution", "notes": "The chart highlights a 'Synchronized concentration peak' at 5 hours for both PrimeC components.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/9", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "traction", "function": "show_traction", "notes": "Includes study design parameters (NST002) and key clinical outcomes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/10", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 11, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "Includes details on screen failures and misdiagnosis exclusions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/11", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-11", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_methodology", "function": "present_framework", "notes": "The slide uses a numbered list format to categorize clinical trial endpoints.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/12", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-12", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "appendix_methodology", "function": "analyze_data", "notes": "The slide defines the statistical populations used for the clinical trial results.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/13", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-13", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "appendix_methodology", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/14", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "appendix_data", "function": "analyze_data", "notes": "Shows balanced enrollment across key metrics like age, BMI, and disease severity (ALSFRS-R).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/15", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-15", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 16, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights clinical trial safety data for PrimeC.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/16", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-16", "loopMatches": [ { "to": 17, "from": 16, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "eac28707-c928-4f11-b43c-15fe53094ee6", "evidence": "The document presents data showing that PrimeC significantly attenuated disease progression by 37% in ALSFRS-R.", "position": 1, "objective": "How does PrimeC compare to placebo in terms of disease progression?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "traction", "function": "show_traction", "notes": "The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/17", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-17", "loopMatches": [ { "to": 17, "from": 16, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "eac28707-c928-4f11-b43c-15fe53094ee6", "evidence": "The document presents data showing that PrimeC significantly attenuated disease progression by 37% in ALSFRS-R.", "position": 1, "objective": "How does PrimeC compare to placebo in terms of disease progression?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "context", "function": "establish_context", "notes": "The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/18", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-18", "loopMatches": [ { "to": 19, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b3aafb36-7f5f-45f1-8a8b-bb4f4179cf96", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R scale, emphasizing the importance of effective treatment.", "position": 0, "objective": "What is the cost of not treating ALS effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 19, "slideType": "traction", "function": "show_traction", "notes": "The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/19", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-19", "loopMatches": [ { "to": 19, "from": 18, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "b3aafb36-7f5f-45f1-8a8b-bb4f4179cf96", "evidence": "The document highlights the significant impact of losing or keeping a single point on the ALSFRS-R scale, emphasizing the importance of effective treatment.", "position": 0, "objective": "What is the cost of not treating ALS effectively?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.6, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 20, "slideType": "traction", "function": "analyze_data", "notes": "The slide uses a human body diagram to categorize ALS symptoms and bar charts to show the reduction in point loss (slower disease progression) for each category.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/20", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-20", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 21, "slideType": "traction", "function": "show_traction", "notes": "The chart highlights a 17.2% attenuation in the decline of SVC score for the PrimeC group compared to placebo.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/21", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-21", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "solution", "function": "present_solution", "notes": "The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like MGH and Harvard.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/22", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-22", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 23, "slideType": "comparison_table", "function": "cite_precedent", "notes": "The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/23", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "solution", "function": "present_solution", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/24", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-24", "loopMatches": [ { "to": 25, "from": 24, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e681d414-7700-4a5b-99a5-b22bec923cbe", "evidence": "The document mentions the potential for PrimeC in Alzheimer's disease, highlighting its broad therapeutic potential.", "position": 2, "objective": "What is the potential for PrimeC in other neurodegenerative diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [ { "to": 24, "from": 6, "beatId": "34d973c9-414c-4e7d-9b2b-216172775550", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 25, "slideType": "traction", "function": "show_traction", "notes": "The slide presents clinical biomarker data (Aβ40, Aβ42, Tau, pTau, PgJ2) comparing control vs AD groups, analyzed via Mann-Whitney U test.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/25", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-25", "loopMatches": [ { "to": 25, "from": 24, "name": "Quick Win Big Bet", "slug": "47-quick-win-big-bet", "bestFor": "Transformation planning, 100-day plans, resource allocation", "matchId": "e681d414-7700-4a5b-99a5-b22bec923cbe", "evidence": "The document mentions the potential for PrimeC in Alzheimer's disease, highlighting its broad therapeutic potential.", "position": 2, "objective": "What is the potential for PrimeC in other neurodegenerative diseases?", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "confidence": 0.6, "description": "Separate initiatives into immediate wins and longer-term strategic bets" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 26, "slideType": "appendix_methodology", "function": "plan_implementation", "notes": "The slide outlines the methodology for a Phase 2 clinical trial for Alzheimer's Disease (AD).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/26", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-26", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-87a3-715f-b988-6da9cfb3fd56", "docSlug": "560176b410a72a6b2e67af5dd2a20758", "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides", "authorId": "neurosense-therapeutics", "authorName": "NeuroSense Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 27, "slideType": "team_bio", "function": "other", "notes": "The slide uses a grid layout to present headshots and credentials, with institutional logos aligned below each relevant member.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/27", "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56", "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-27", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }